 The FDA has approved Takeda Pharmaceutical Co Ltds NYSE: TAK Exkivity mobocertinib for non-small cell lung cancer NSCLC settings. The approval comes for adult patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. 